Medical News & Research

24 hours ago

ROS1-positive NSCLC: Taletrectinib FDA-approved with high response rates in TKI-naive disease

Approval is based on two multicenter single-arm trials totaling 157 ROS1 TKI-naive patients with ORR 85% to 90% and most responses lasting at least 12 months; key labeled risks include hepatotoxicity, ILD and QTc prolongation.

FDA
2 days ago

MSI-H/dMMR locally advanced rectal cancer: dostarlimab enables sustained clinical complete responses and organ preservation

FDA accelerated approval is based on single-arm multicenter trials where 47% achieved 12-month sustained cCR by independent central review and most patients avoided chemoradiation and surgery without progression at median 26 months.

FDA
2 days ago

Severe fetal CNS anomalies: add exome sequencing to chromosomal microarray as first-tier testing

In a decision-analytic Markov cost-effectiveness model over 20 years, chromosomal microarray plus exome sequencing dominated microarray alone with higher QALYs and markedly lower expected cost per pregnancy driven by avoided long-term disability costs.

International Journal of Gynecology & Obstetrics
2 days ago

ROS1-positive NSCLC: taletrectinib wins FDA approval with high response rates

Approval is based on two multicenter single-arm open-label trials totaling 270 patients, showing ORR 85% to 90% in ROS1 TKI-naive disease and 52% to 62% after prior ROS1 TKI, with key safety warnings including hepatotoxicity, ILD and QTc prolongation.

FDA
Clinical Relevance: High